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Summary
Background The emergence and spread of high levels of HIV-1 drug resistance in resource-limited settings where 
combination antiretroviral treatment has been scaled up could compromise the eﬀ ectiveness of national HIV 
treatment programmes. We aimed to estimate changes in the prevalence of HIV-1 drug resistance in treatment-naive 
individuals with HIV since initiation of rollout in resource-limited settings.
Methods We did a systematic search for studies and conference abstracts published between January, 2001, and July, 
2011, and included additional data from the WHO HIV drug resistance surveillance programme. We assessed the 
prevalence of drug-resistance mutations in untreated individuals with respect to time since rollout in a series of 
random-eﬀ ects meta-regression models. 
Findings Study-level data were available for 26 102 patients from sub-Saharan Africa, Asia, and Latin America . We 
recorded no diﬀ erence between chronic and recent infection on the prevalence of one or more drug-resistance 
mutations for any region. East Africa had the highest estimated rate of increase at 29% per year (95% CI 15 to 45; 
p=0·0001) since rollout, with an estimated prevalence of HIV-1 drug resistance at 8 years after rollout of 7·4% (4·3 to 
12·7). We recorded an annual increase of 14% (0% to 29%; p=0·054) in southern Africa and a non-signiﬁ cant increase 
of 3% (–0·9 to 16; p=0·618) in west and central Africa. There was no change in resistance over time in Latin America, 
and because of much country-level heterogeneity the meta-regression analysis was not appropriate for Asia. With 
respect to class of antiretroviral, there were substantial increases in resistance to non-nucleoside reverse transcriptase 
inhibitors (NNRTI)  in east Africa (36% per year [21 to 52]; p<0·0001) and southern Africa (23% per year [7 to 42]; 
p=0·0049). No increase was noted for the other drug classes in any region.
Interpretation Our ﬁ ndings suggest a signiﬁ cant increase in prevalence of drug resistance over time since antiretroviral 
rollout in regions of sub-Saharan Africa; this rise is driven by NNRTI resistance in studies from east and southern 
Africa. The ﬁ ndings are of concern and draw attention to the need for enhanced surveillance and drug-resistance 
prevention eﬀ orts by national HIV treatment programmes. Nevertheless, estimated levels, although increasing, are 
not unexpected in view of the large expansion of antiretroviral treatment coverage seen in low-income and middle-
income countries—no changes in antiretroviral treatment guidelines are warranted at the moment.
Funding Bill & Melinda Gates Foundation and the European Community’s Seventh Framework Programme
Introduction
In response to the global HIV epidemic, a WHO-
recommended public health approach to antiretroviral 
therapy (ART) has been widely implemented in 
resource-limited countries.1,2 At the end of 2011, more 
than 8 million people were receiving antiretroviral 
therapy in low-income and middle-income countries—
which was 26 times higher than the number from 
December, 2003.3 Successful ART rollout in resource-
limited settings has used standard treatment protocols, 
simpliﬁ ed monitoring of patients, and decentralised 
service delivery. First-line regimens were based on non-
nucleoside reverse transcriptase inhibitors (NNRTI), 
with protease inhibitors reserved for second-line 
treatment.
Although ART rollout in resource-limited settings 
has used highly active triple combination therapy, 
national health systems in such areas often have limited 
infrastructure, a shortage of health professionals, in-
consistent supply chains, and weak enforcement of 
quality standards. Although HIV/AIDS-related mortality 
in sub-Saharan Africa has substantially fallen since the 
widespread distribution of ART,4 data suggest that up to 
24% of patients receiving ﬁ rst-line ART in sub-Saharan 
Africa have virological failure within 12 months of 
initiation of ﬁ rst-line ART.5 Between 53% and 90% of 
these patients have viruses with clinically important 
HIV-1 drug resistance to NNRTIs and nucleoside reverse 
transcriptase inhibitors (NRTIs).6–9 Thus, there is concern 
about onward transmission of drug-resistant strains after 
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ART scale-up. Moreover, pretreatment drug resistance, 
which can be transmitted or acquired through prophyl-
actic or other ART exposure, has the potential to 
contribute to the increasing rates of virological failure 
at a population level, thus compromising long term 
eﬀ ectiveness of recommended ﬁ rst-line regimens. Large 
studies have reported increases in the chance of 
virological failure of two-to-three times within 12 months 
of initiation of ART in populations in which resistance to 
components of standard ﬁ rst-line treatment is detected 
before the start of ART.10
In view of the serious public health implications 
associated with the emergence and transmission of drug-
resistant HIV in resource-limited settings, WHO devel-
oped a global strategy to assess population-level HIV drug 
resistance in deﬁ ned geographical areas of countries.11 As 
part of this strategy, standardised sur veillance is done to 
assess resistance in recently12 and chronically infected13 
populations initiating ART.
Since ART rollout in resource-limited settings, trends 
in prevalence and patterns of resistance in untreated 
patients with HIV have not been systematically assessed 
at a global level. We have undertaken a comprehensive 
assessment of available data. We aimed to estimate 
changes since initiation of rollout in the prevalence of 
HIV drug resistance in untreated HIV-infected popu-
lations worldwide, and to investigate the frequencies of 
drug-resistance mutations of public health importance.
Methods
Identiﬁ cation of studies
We searched for studies written in English from 
PubMed and Embase, and conference abstracts and 
presentations from Conference on Retroviruses and 
Opportunistic Infections, International AIDS Society 
Conference, and the International Drug Resistance 
Workshop for the 10-year period between Jan 01, 2001, 
and July 31, 2011. We used the following search terms: 
“antiretroviral therapy” AND “transmitted drug 
resistance”; “anti retroviral therapy” AND “(stavudine OR 
zidovudine OR nevirapine OR efavirenz)”; “HIV” AND 
“transmitted drug resistance”; “HIV” AND “antenatal”; 
“HIV” AND “VCT”; “genotyp*” AND “HIV” AND 
“naïve”; “genotyp*” AND “HIV” AND “resistance”; and 
“genotyp*” AND “HIV” AND “resistance” AND 
“primary”. We included studies in untreated adults 
(aged >15 years) recently or chronically infected from 
low-income and middle-income countries in western 
Paciﬁ c region, southeast Asia, sub-Saharan Africa, and 
Latin America and the Caribbean. We included studies if 
they reported at least ten genotypes in untreated patients 
with HIV-1 using standard population sequencing. We 
included studies of the prevention of mother-to-child 
transmission when they provided data for drug resis-
tance before anti retroviral drug exposure in preg nant 
women.  We excluded studies if they used non-population 
genotyping methods such as single-genome sequencing, 
allele-speciﬁ c PCR, and ultra-deep sequencing. We also 
in cluded data from national surveys that used WHO-
recommended methods to assess resistance in both 
recently infected individuals  and chronically infected 
patients initiating ART.
Data abstraction
Two reviewers (RKG, BJS) independently assessed 
studies for eligibility. We extracted the following data: 
country; year of sample collection; sex; study type; risk 
groups; setting (rural, peri-urban, urban); HIV-1 
subtypes occurring at a prevalence of greater than 10%; 
timing of infection and methods (if any) used to 
distinguish recent versus chronic infection; baseline 
CD4 cell count; number of baseline genotypes; number 
of patients with more than one drug-resistance 
mutation, one or more NRTI mutation, one or more 
thymidine analogue mutation, one or more NNRTI 
mutation, and one or more protease inhibitor mutation. 
Most studies done after 2007 reported drug-resistance 
mutations in recently infected individuals according to 
the WHO Surveillance Drug Resistance Mutations 
List.14 Studies of resistance in chronically and recently 
infected people done before 2007 reported drug 
resistance mutations according to other lists such as the 
International AIDS Society–USA Drug Mutation list, 
the Stanford Drug Resistance Database list, or, in a few 
cases, the ANRS (French National Agency for AIDS 
Research) list. We classiﬁ ed as being recently infected 
individuals included in the WHO surveys of transmitted 
drug resistance, and individuals identiﬁ ed as being 
recently infected through serial antibody testing or a 
detuned antibody algorithm (table 1).12 WHO trans-
mitted drug resistance survey methods used epidemio-
logical or laboratory criteria, or both, to maximise the 
likelihood that participants will have been infected with 
HIV within the past 3 years and limit the likelihood of 
previous exposure to antiretroviral drugs. Criteria are: 
age younger than 25 years and, if female, no previous 
pregnancy; when available, documented laboratory 
evidence of recent infection or seroconversion or CD4 
count higher than 500 cells per mm³. When studies did 
not follow the WHO-recommended method, deﬁ nitions 
of recent infection were however relatively consistent 
with WHO criteria. Many studies assessing resistance 
in chronically infected individuals included patients 
about to initiate antiretroviral therapy. Studies were 
initially grouped according to WHO geographical 
classiﬁ cations as follows: Africa, southeast Asia, 
western Paciﬁ c, and the Americas. Because we included 
studies from only resource-limited settings, we used 
the term Latin America and the Caribbean instead of 
the Americas. For the analysis presented, western 
Paciﬁ c and southeast Asian countries were grouped as 
Asia (ﬁ gure 1). Individual-level data were not available 
for the studies and we therefore analysed study-level 
data only.
For the Stanford Drug 
Resistance Database list see 
http://hivdb.stanford.edu/
For the ANRS list see http://
www.hivfrenchresistance.org/
For WHO geographical 
classiﬁ cations see http://www.
who.int/about/regions/en/index.
html
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Statistical analysis
We did an exploratory analysis and determined pooled 
proportions of the number of individuals with drug-
resistant mutations (r) in those successfully genotyped 
(n). To assess heterogeneity in proportions between 
studies and across geographical locations, the variances 
of the raw proportions (p = r / n) were stabilised with 
the following Freeman-Tukey-type arcsine square root 
transformation:15,16
y = arcsine[√(r / (n + 1)] + arcsine[√(r + 1) / (n + 1)],
with a variance of 1 / (n + 1)
We assessed heterogeneity between studies by pooling 
studies using DerSimonian-Laird weighting and as sess-
ing the I² statistic of the meta-analysis of the transformed 
proportions.
Because this preliminary pooled analysis showed much 
heterogeneity within and between continents, we divided 
Africa into regions (west and central, southern, and east) 
and aimed to further explore whether the following 
covariates were potential causes: duration of infection 
(recent vs chronic), risk group (ie, men who have sex with 
men, heterosexual contact, intravenous drug users, 
female sex workers); diﬀ erences in geno typing methods 
and methods used to interpret the eﬀ ect of mutations on 
drug resistance, and population-based measures of ART 
availability. We deﬁ ned two population-based metrics of 
ART availability: time since rollout and ART coverage. 
The appendix provides the rollout dates by country.  ART 
coverage in a particular country was deﬁ ned as the 
number of people recieving ART in a given year divided 
by the WHO estimate of people with HIV (diagnosed or 
undiagnosed) in the same year in that country. 
Figure 1: Countries contributing data by regions and subregions
Latin America and
the Caribbean
West and central Africa
Southern Africa
East Africa
Asia
Number of 
patients 
(number of 
studies)
Median 
number of 
genotypes per 
study (range)
Median sampling 
year (range)
Studies in 
recently 
infected 
populations 
(n [%])
Genotypes 
from recently 
infected 
populations 
(n [%])
Number of studies 
using deﬁ ned 
epidemiological 
criteria for recent 
infections (% of 
studies in recently 
infected people)
Studies in 
populations 
about to start 
antiretroviral 
treatment (% of 
studies in 
chronically 
infected people)
East Africa 4300 (33) 78 (11–570) 2005 (1993–2010) 18 (55%) 1107 (26%) 14 (78%) 4 (25%)
Southern Africa 6251 (47) 71 (21–570) 2006 (1998–2009) 22 (46%) 2026 (32%) 21 (95%) 5 (20%)
West and central Africa 3211 (40) 79 (18–271) 2005 (1998–2009) 14 (35%) 1090 (34) 13 (93%) 3 (12%)
Asia 5635 (50) 61 (11–676) 2006 (1999–2010) 24 (48%) 2276 (40%) 16 (67%) 2 (8%)
Latin America and the 
Caribbean
6705 (48) 60 (16–1655) 2004 (1995–2009) 12 (25%) 1346 (21%) 2 (17%) 0
Table 1: Characteristics of included studies, by region
See Online for appendix
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Heterogeneity in study level mutation estimates resulting 
from location (urban vs rural) could not be explored 
because of the small number of studies undertaken 
exclusively in rural settings. Furthermore, we did not 
explore heterogeneity by the proportion of women in each 
study because of its strong relation with risk group, as 
well as the fact that a quarter of studies did not report sex 
ratios. Although a range of genotyping methods was used 
across studies, published data suggest that commercially 
available genotyping methods and in-house reference 
laboratory methods give similar results.17,18 Furthermore, 
laboratories contributing data to WHO surveys have 
undergone a standardised external quality assurance 
programme.19 Finally, because there are subtle diﬀ erences 
between mutation lists used to identify mutations in the 
studies included (eg, some lists call a change at a speciﬁ c 
position a mutation whereas others do not) a possibility 
exists that bias was introduced, although, as shown 
previously,20 this bias is likely to be negligible. Accordingly, 
only duration of infection, time since rollout, and ART 
coverage were assessed further.
To assess these potential causes of heterogeneity, we 
used logistic regression models with a random eﬀ ect at 
study level to allow for between-study heterogeneity 
previously shown to perform well for meta-analyses of 
binomial data with few events.21 In studies with no muta-
tions, the proportion was estimated as: 1 ÷ (4 × n). Meta-
regression models indicated that duration of infection was 
not related to the proportion of drug-resistant mutations 
(p=0·92). Because the prevalence of drug-resistance 
mutations was not diﬀ erent between chronic or recently 
infected populations, we considered these groups together 
in subsequent analyses. Analyses involving metrics of 
ART availability indicated that associations between time 
since ART rollout and prevalence of drug-resistance 
mutations varied across geographical regions (ie, there 
was a signiﬁ cant interaction between region and time 
since rollout; p<0·0004). Therefore, we analysed 
associations between ART availability metrics and 
prevalence of mutation separately for each geographical 
region. In Asia, there was an interaction at the country-
level (India, China, Vietnam, Thailand; p<0·0001); there 
were too few studies to do a country-level meta-regression. 
Therefore, to describe drug resistance at the country level 
we derived pooled estimates using the Freeman-Tukey-
type arcsine square root transformation—we used the 
DerSimonian-Laird random eﬀ ects method to pool the 
transformed proportions. The outcome of the meta-
regression model was the proportional change in 
resistance from one year to the next, reported as an odds 
ratio (the odds ratio is very similar to the proportional 
percentage change at low prevalence; therefore, the odds 
ratio was reported as percentage change per year for ease 
of inter pretation).
We also did the above analyses to estimate the 
prevalence of drug-class-speciﬁ c mutations (thymidine 
analogue mutations, NNRTI, and protease inhibitor 
mutations) by region and in respect to its variation with 
ART availability (time since rollout and ART coverage).
Prevalence of thymidine analogue, NNRTI, and 
protease inhibitor mutations, as well as prevalence of 
selected individual mutations as a proportion of all 
people with drug resistance were pooled with random-
eﬀ ects meta-analysis, with the Tukey transformation and 
DerSimonian-Laird weightings, as previously described. 
We used Stata (version 11.2) and SAS (version 9.1.3) for 
all statistical analyses.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. MRJ had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication. 
Results
We analysed 191 datasets from 162 individual reports 
spanning 42 countries (ﬁ gure 2), and an additional 
27 datasets from the WHO HIV drug resistance 
surveillance programme. Overall, study level data were 
available for 26 102 patients—there were similar numbers 
of studies reporting drug resistance data for recently and 
chronically infected individuals in all regions except Latin 
America and the Caribbean and west and central Africa, 
where only about 30% of studies were reported to be in 
Figure 2: Study selection
11 223 studies identiﬁed
10 759 excluded on the basis 
of title or abstract
464 full-length papers or abstracts assessed
302 reports excluded
52 in-vitro studies
8 case reports
30 reviews
3 modelling or statistical studies
2 economic studies
55 North American or European study
61 no resistance data
50 non-resistance clinical studies
11 epidemiological studies
3 co-infection studies
4 non-HIV studies
3 individuals exposed to
antiretroviral treatment
5 studies in children
5 merged country data
2 fewer than ten patients
6 non-population-based 
sequencing studies
2 duplicated studies
162 reports included in analysis (191 datasets)
Articles
1254 www.thelancet.com   Vol 380   October 6, 2012
recently infected individuals (table 1). 14 (7% of 191) 
studies recruited chronically infected individuals 
attending ART clinics initiating patients on ﬁ rst-line 
treatment—the remaining studies reported data derived 
from voluntary counselling and testing facilities, hospitals, 
blood donation centres, or pathology laboratories. Of the 
studies examin ing recent infection, 33 studies (37% of 90) 
studies recruited from antenatal clinic sites  and 47 studies 
(52% of 90) recruited from voluntary counselling and 
testing sites—the remaining studies reported data derived 
from hospitals, blood donation centres, or pathology 
labora tories. Our analysis showed no diﬀ erence between 
chronic and recent infection in the prevalence of one or 
more drug-resistance mutation for any region. The vast 
majority of studies were in individuals with heterosexual 
risk or in mixed populations (only four [2%] studies were 
done in men who have sex with men and, with two [1%] 
done in intravenous drug users). Similarly, the vast 
majority of studies were done in urban, peri-urban, or a 
mixture of urban and rural populations (only seven [4%] 
studies were undertaken in purely rural populations). 
Because data for ART coverage were available from only 
2003 onwards, 53 studies (28% of all eligible studies) were 
not included in this analysis and therefore results are not 
directly comparable with the primary analysis based on 
time since rollout. Drug resistance data for both measures 
of ART availability are summarised in the appendix.
East Africa had the highest average modelled rate of 
increase in prevalence of any drug-resistance mutations 
at 29% per year (95% CI 15 to 45; p=0·0001) since rollout, 
with a strong association between prevalence of any 
drug-resistance mutation and ART coverage (p=0·0013) 
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Figure 3: Prevalence of drug resistance in treatment-naive trial participants with HIV-1, by time since antiretroviral rollout
(A) East Africa. (B) Southern Africa. (C) West and central Africa. (D) Latin America and the Caribbean. Every circle is a study and the size of the circle is proportional to the precision of the estimate from 
the individual study, with sizes comparable within individual graphs only. The trend line is predicted prevalence.
0–2 years after 
ART rollout
3–4 years after 
ART rollout
5–7 years after 
ART rollout
8–9 years after 
ART rollout
p value
East Africa 0·9 (0·5–1·6) 3·5 (2·1–5·7) 5·1 (2·6–9·9) 7·4 (4·2–12·9) 0·0006
Southern Africa 2·1 (1·6–2·6) 2·3 (1·6–3·3) 3·7 (2·5–5·4) ·· 0·0006
West and central Africa 1·8 (1·1–3·1) 5·7 (4·0–8·0) 3·5 (2·5–5·0) ·· 0·43
Latin America and the 
Caribbean
5·9 (4·1–8·4) 6·5 (4·7–9·0) 3·9 (2·7–5·8) 7·6 (4·8–12·2) 0·50
Data are % of population with with one more mutation as deﬁ ned by the WHO surveillance drug resistance mutations 
list (95% CI). ··=no studies done 8–9 years after rollout.
Table 2: Sensitivity analysis showing proportion of individuals with one or more drug-resistance 
mutation, by region and years after rollout of antiretroviral treatment (ART)
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(ﬁ gure 3 and appendix). Our modelled estimates suggest 
that the prevalence of any drug resistance in east Africa 
at rollout was 1·0% (0·6 to 1·9), and 7·4% (4·3 to 12·7) 
8 years later. The estimated annual rate of increase was 
14% (0 to 29; p=0·054) in southern Africa and 3% (–9 to 
16; p=0·618) in west and central Africa (ﬁ gure 3), with 
estimated prevalences of resistance at rollout of 1·4% 
(0·8 to 2·3) and 3·1% (1·7 to 5·6), respectively. ART 
coverage did not seem to be associated with the 
prevalence of drug resistance in southern (p=0·88) or 
west and central Africa (p=0·55).
We did a sensitivity analysis of changes in drug 
resistance prevalence over time. We calculated inverse 
variance weighted prevalence of any drug-resist ance 
mutation for each region in blocks of 2 years after rollout. 
This sensitivity analysis showed increasing drug resis-
tance since rollout in east Africa and southern Africa 
(p=0·0006 for both), but not in west and central Africa 
(p=0·43) or in Latin America (p=0·50; table 2).
Because of country-level heterogeneity in Asia, regional 
analysis was inappropriate. Furthermore, there were too 
few studies from Asian countries to do formal country-
level meta-regression analyses. Of Asian countries, most 
studies were from Thailand, China, India, and Vietnam 
(table 3). Thailand had the lowest overall prevalence of 
any drug resistance. Studies done in Vietnam reported 
the highest prevalence of drug-resistance mutations. 
There were also pronounced diﬀ erences in the prevalence 
of resistance at or before the start of rollout between 
countries (appendix).
For Latin America and the Caribbean, there was no 
eﬀ ect of time since rollout of ART on prevalence of drug 
resistance (p=0·960) nor was there an association 
between ART coverage and prevalence of drug resistance 
in the 25 studies done from 2003 onwards that had 
coverage data available (p=0·052; ﬁ gure 3 and appendix). 
The estimated prevalence of any drug-resistance mutation 
in Latin America and the Caribbean 8 years after rollout 
was 6·9% (5·6 to 8·4), with the prevalence of drug-
resistance mutations at the start of rollout being 6·9% 
(5·0 to 9·5; ﬁ gure 3).
With respect to class of antiretroviral drugs, in east 
Africa, there was a substantial increase in NNRTI 
resistance over time since rollout—36% per year (21 to 
52; p<0·0001; ﬁ gure 4). Southern Africa showed an 
increase of 23% per year (7 to 42%; p=0·0049); west and 
central Africa had a non-signiﬁ cant increase of 15% per 
year (–1 to 32; p=0·0646; appendix), and the estimated 
prevalence of NNRTI resistance was 5·1% (3·1–8·2) 
8 years after rollout in east Africa. The prevalence of 
thymidine analogue mutations, which can reduce the 
eﬀ ectiveness of second-line NRTI drugs, seemed to 
increase with time since rollout in east Africa (31% per 
year [4–66]; p=0·021), but no signiﬁ cant changes were 
noted in other regions (appendix).
In view of the increasing prevalence of HIV drug 
resistance in parts of sub-Saharan Africa, the identiﬁ -
cation of signature mutations for surveillance purposes 
might be useful in the future. NNRTI mutations were 
the most commonly seen mutations, occurring in 
40–60% of patients with one or more drug-resistance 
mutation, and showed some variation by region 
(appendix). For NNRTI resistance, the weighted preva-
lence of the K103N/S mutation was about 60% and 25% 
for Y181C/I/V in individuals with any DRM. The 
weighted prevalence of M184V/I, which confers high-
level lamivudine resistance, was 8% (appendix).
Discussion
Our ﬁ ndings suggest a signiﬁ cant increase in prevalence 
of drug resistance over time since antiretroviral rollout in 
regions of sub-Saharan Africa; this rise is driven by 
NNRTI resistance in studies from east and southern 
Africa. In east Africa, resistance increased at almost 30% 
per year. Despite the steep increase in east Africa, we do 
not recommend extrapolation of this trend beyond the 
period covered by the data. Our estimate for increase in 
drug resistance in southern Africa was 14% per year, and 
no increase over time was noted in west and central 
Figure 4: Prevalence of major drug-resistance mutations that confer 
resistance to non-nucleoside reverse transcriptase inhibitors, by time since 
antiretroviral rollout in east Africa
Size of circle is proportional to the precision of the estimate from the individual 
study, with sizes comparable within individual graphs only. The trend line is 
predicted prevalence. DRM=drug-resistance mutation. NNRTI=non-nucleoside 
reverse transcriptase inhibitor.
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Years since rollout
Number of 
study groups
Median sampling year 
(range)
Mean time since 
scale-up (years 
[range])
Weighted prevalence of 
drug-resistance mutations 
(95% CI)
Thailand 12 2005 (2000–09) 4·3 (0·5–9·0) 0·5% (0·1–1·4)
China 15 2006 (2001–10) 4·0 (0–7·5) 2·6% (1·4–4·1)
India 10 2007 (1999–10) 2·7 (0–6·0) 2·7% (1·1–4·7)
Vietnam 9 2008 (2006–09) 2·5 (1·0–4·0) 4·5% (3·3–6·0)
Data are given for only those countries with ﬁ ve or more studies. Not included in this table are Indonesia (n=1) and 
Cambodia (n=3).
Table 3: Characteristics of studies from four Asian countries
Articles
1256 www.thelancet.com   Vol 380   October 6, 2012
Africa. We saw no change over time in Latin America 
and the Caribbean. Because of heterogeneity between 
countries in Asia, we were unable to assess time trends 
in this region and there were too few data at country level 
to do formal meta-regression analysis. The increasing 
prevalence of resistance is not unexpected in view of the 
large expansion of ART coverage seen in low-income and 
middle-income countries.
The most important transmitted drug-resistance muta-
tions in the context of ART rollout are single amino acid 
mutations conferring high-level resistance to NNRTIs, in 
view of the fact that NNRTIs are the foundation of 
available ﬁ rst-line ART and prevention of mother-to-child 
transmission regimens. These muta tions have been 
associated with treatment failure in cases in which they 
exist before the initiation of ﬁ rst-line treatment.10,22,23 We 
estimated a 36% increase in preva lence of NNRTI 
mutations per year in east Africa and 23% per year in 
southern Africa. Our ﬁ ndings show that more than half 
of HIV-infected African patients with NNRTI resistance 
harbour viruses with the K103N mutation, and, therefore, 
that detection of this sentinel mutation might be useful 
in expanded surveillance activities for estimation of the 
prevalence of NNRTI resistance. Studies from east Africa 
that reported high prevalence of NNRTI resistance in 
recently infected adults excluded women with previous 
pregnancy,24,25 or enrolled patients infected within the 
past year,26 dis counting the possibility that the NNRTI 
resistance is a consequence of the use of single-dose 
nevirapine in mothers for the prevention of transmission 
to their child.
Several possible explanations exist for the regional 
diﬀ erences in our modelled time trends. The scale-up of 
ART has occurred at variable rates, and with variable 
country coverage,27 both of which will determine 
transmission of resistant viruses. ART coverage itself is 
associated with the proportion of individuals with HIV 
who have been diagnosed, which might also vary between 
regions of sub-Saharan Africa. ART programme 
functioning (as assessed by indicators such as patient 
adherence, drug supply, drug regimens used, and 
treatment success) could contribute to the diﬀ erences 
seen between regions. For example, the achievement of 
high levels of ART coverage in the context of suboptimum 
programme functioning might result in the greatest 
increases in HIV drug resistance over time. Finally, the 
availability of ART was inconsistent outside the public 
sector already in the pre rollout era in most countries, and 
this variability is shown by the detection of some level of 
resistance close to or at the start of rollout (ﬁ gure 3). West 
and central Africa had a higher preva lence of drug 
resistance at the time of rollout than did other parts of 
sub-Saharan Africa (ﬁ gure 3) and this uneven distribution 
might aﬀ ect the dynamics of drug resistance over time.
We used country-level ART coverage data as an 
alternative measure of ART availability. Although data 
were available for only 72% of studies (those done before 
2003 did not have coverage data), this analysis showed a 
strong relation for increase in HIV drug resistance in 
east Africa with coverage (appendix).
Data included in this analysis are unlikely to represent 
national prevalence of HIV drug resistance because most 
studies were done in urban areas where ART coverage 
(and pre rollout ART use) is likely to be substantially 
higher than are national averages. However, over time, 
levels of HIV drug resistance in regions within a country 
can be expected to be more evenly distributed because of 
greater penetration of ART into rural areas and because 
cross-transmission between rural and urban populations 
is likely to occur.
Hamers and colleagues28 reported the results of a 
multicentre cohort study of 2590 patients done in South 
Africa, Zambia, Zimbabwe, Uganda, and Kenya. Their 
pooled-analysis of data from areas surveyed in these 
countries showed a correlation between the time since 
start of ART rollout and the prevalence of at least one 
drug-resistance mutation and NNRTI resistance. Find-
ings from small observational studies have suggested an 
increase in the prevalence of HIV drug resistance over 
time in Kampala, Uganda,24 and Yaounde, Cameroon.29 
Added to the ﬁ ndings of these studies, the data reported 
here provide region-speciﬁ c quantiﬁ cation of changes in 
prevalence of drug resistance after the rollout of ART.
The consequences of increasing HIV drug resistance 
in patients who are starting ART are substantial, and 
include: increased treatment failure rates with greater 
morbidity and mortality, increased need for more 
expensive second-line regimens, and costs associated 
with further transmission of more highly resistant and 
potentially untreatable viruses.
A crucial outcome of this analysis is that countries 
in resource-limited settings should routinely do 
population-level resistance surveillance as part of national 
treatment programmes. Although a full cost-eﬀ ectiveness 
analysis of strategies to limit HIV drug resistance is not 
available, the cost of implementing a survey of transmitted 
drug resistance in a speciﬁ c geographical area with WHO 
methods is inexpensive, ranging from US$30 000 to 
$60 000 per survey when compared with the total cost of 
ART rollout (Bertagnolio S, unpublished). However, the 
biggest barriers to the surveillance of HIV drug resistance 
are the restricted capacity of local labora tories, inade-
quate general infrastructure and human resources, and, 
possibly, a restricted under standing of the value of sur-
veillance information and how it can be used to guide 
policy. A cheaper and simpler resistance-testing platform 
potentially involving point mutation assay methods 
designed to identify key NNRTI mutations of public 
health interest with dried blood spots might encourage 
countries to routinely monitor resistance at the popu-
lation level.30,31
In addition to heightened surveillance, continued 
monitoring and adjustment of programmatic factors that 
lead to the emergence and spread of resistance to ART are 
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needed.13 Bennett and colleagues32 assessed data from more 
than 2000 clinics in 50 countries worldwide between 2004 
and 2009 by means of WHO-deﬁ ned early warning 
indicators for drug resistance. This study documented 
stock-outs of antiretroviral drugs in about 40% of monitored 
sites in sub-Saharan Africa.32 This problem could be 
addressed through improved supply management systems 
that would ensure un interrupted availability of ART. 40% of 
ART programmes in sub-Saharan Africa were reported to 
have more than 20% loss to follow-up. Problems with 
retention of patients are further barriers to successful, 
sustained viral suppression at the population level.32
Other potential strategic implications of our ﬁ ndings 
include the rapid scale-up of routine viral-load testing to 
enable timely detection and management of treatment 
failure to limit the emergence of HIV drug resistance.6,33 
The prevalence of thymidine analogue mutations is 
explained by the extensive use of thymidine analogues in 
resource-limited settings. Accumulation of thymidine 
analogue mutations might reduce the eﬀ ectiveness of 
second-line tenofovir-containing combinations.7,34 Bet ter-
tolerated ﬁ rst-line regimens (containing tenofovir) could 
become more widely used in the future and might 
contribute to the lowering of HIV drug resistance 
through improved adherence.35
In areas where pre-treatment NNRTI drug resistance 
exceeds an as yet undetermined threshold, a change 
from NNRTI-based ﬁ rst-line treatment to boosted pro-
tease inhibitors might improve rates of viral suppression 
and reduce treatment-emergent drug resistance.36,37 
Economic and programmatic assessment would inform 
decision making regarding the population prevalence 
level at which change in ﬁ rst-line regimen, individu-
alised pretreatment genotyping, or intensiﬁ ed viral load 
monitoring with early regimen switch would become 
cost eﬀ ective.
Our study had several limitations. Our search strategy 
was restricted to only English-language articles. There 
were also limitations in our analysis of summary data 
from diﬀ erent groups of patients over time—eg, the 
samples of patients might diﬀ er in ways not controlled for 
in the analysis despite allowing for random eﬀ ects in the 
analyses. Furthermore, although heterogeneity has been 
extensively considered and assessed in our analysis, there 
might be unexplained sources of heterogeneity in the 
dataset. The paucity of studies from rural settings means 
that the analysis shows transmitted drug resist ance in 
only urban and peri-urban areas. However, as access to 
ART increases in sub-Saharan Africa, similar trends 
might be expected in rural areas under similar ART 
programmatic conditions. Despite intending to select 
studies of drug-naive populations, our dataset might have 
included data for women who had previously received 
treatment to prevent transmission to their children, and 
for individuals who had previous un disclosed antiretroviral 
exposure. However, pre-existing HIV drug resistance, 
whether due to transmission or undisclosed previous 
treatment, will adversely aﬀ ect the success of ART rollout 
programmes. Finally, diﬀ erences in regimen (zidovudine 
vs stavudine, or protease inhibitor vs NNRTI in some parts 
of Latin America), programme functioning and adherence 
could not be controlled for in the analysis and might play 
a part in regional diﬀ erences. No diﬀ erence in the 
prevalence of mutations was noted between recently and 
chronically infected populations, which might be because 
of the heterogeneity of the criteria used to assess recent 
versus chronic infection in the studies included in the 
Article, leading to potential misclassiﬁ cation bias. 
Additional research based on standardised deﬁ nitions of 
duration of infection is needed to conﬁ rm this ﬁ nding.
Continued commitment remains essential to reach the 
goal of universal access and improve the quality of HIV 
care and treatment in resource-limited settings. We have 
shown that HIV drug resistance in untreated patients 
has been increasing in some areas of sub-Saharan Africa 
since ART rollout. In view of these concerning ﬁ ndings, 
urgent strategic action is clearly needed to maximise the 
long-term eﬀ ectiveness of available ﬁ rst-line regimens, 
and eﬀ orts should be focused on the optimisation of the 
functioning of national HIV treatment programmes. 
This optimisation would involve the establishment of 
robust supply chains to prevent drug stock-outs and 
treatment interruptions, scale-up of routine viral load 
monitoring to detect early failures, expanded access to 
alternative drug regimens, and the development of 
meaningful and sustainable strategies to overcome 
structural barriers to adherence and routine defaulter 
tracing to maximise retention.
Now, more than ever, investment and political will are 
urgently needed to sustain and expand global surveillance 
eﬀ orts. Such investments are essential to maximise the 
eﬀ ectiveness of treatment scale-up. Although still within 
expected levels, further increases in the prevalence of HIV 
drug resistance might jeopardise the global HIV response 
and curb a decade-long trend of decreasing HIV-related 
morbidity and mortality in low-income and middle-income 
countries. However, no changes in antiretroviral treatment 
guidelines are warranted at the moment.
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